A B S T R A C T To delineate the potential role of disordered glucose and glucose-precursor kinetics in the abnormal carbohydrate metabolism of chronic renal failure, alanine and glucose production and utilization and gluconeogenesis from alanine were studied in patients with chronic compensated renal insufficiency and in normal volunteers. With simultaneous primed injection-continuous infusions of radiolabeled alanine and glucose, rates of metabolite turnover and precursor-product interrelationships were calculated from the plateau portion of the appropriate specific activity curves. All subjects were studied in the postabsorption state. In 13 patients with chronic renal failure (creatinine = 10.7±1.2 mg/100 ml; mean+SEM), glucose turnover was found to be 1,035+99.3 ,umol/ min. This rate was increased 56% (P = 0.003) over that observed in control subjects (664±33.5 gmol/min). Alanine turnover was 474±96.0 gmol/min in azotemic patients. This rate was 191% greater (P = 0.007) than the rate determined in control subjects (163±19.4 gmol/min). Gluiconeogenesis from alanine and the percent of glucose production contributed by gluconeogenesis from alanine were increased in patients with chronic renal failure (192% and 169%, respectively) as compared to controls (P < 0.05 for each). Alanine utilization for gluconeogenesis was increased from 40.2 ±3.86 gmol/min in control subjects to 143+39.0 ,umol/min in azotemic patients (P < 0.05). The percent of alanine utilization accounted for by gluconeogenesis was not altered in chronic renal insufficiency. In nondiabetic azotemic subjects, mean fasting glucose and Dr. Garber is an investigator at the Howard Hughes Medical Institute. Received for publication 7 October 1.977 and in revised form 8 Februartj 1978. immunoreactive insulin levels were increased 24.3% (P = 0.005) and 130% (P = 0.046), respectively.
INTRODUCTION
Disordered carbohydrate metabolism is widely recognized in patients with chronic renal failure (1) . These abnormalities most commonly include previously unrecognized carbohydrate intolerance in greater than 50% of azotemic individuals (2, 3) and even overt fasting hyperglycemia (3, 4) . However, the development of spontaneous hypoglycemia has also been reported (5, 6) . On the other hand, an amelioration of the diabetic state with decreasing insulin requirements is a well-known clinical concomitant of advancing renal failure in patients with previously established diabetes mellitus (7) .
Recent work in patients with diabetes mellitus has suggested that an inappropriate and excessive rate of glucose production may function as an important determinant of the degree of hyperglycemia (8) . Additionally, increased gluconeogenesis from a variety of precursors such as alanine, the principal gluconeogenic amino acid, has been demonstrated in patients with diabetes mellitus (9, 10) . Elevated rates of alanine formation and release may have been described in skeletal muscle of chronically uremic rats (11) . Increased hepatic gluconeogenesis has been observed in the acutely uremic rat (12) and in rat liver slices ineuibated in serum obtained from uremic patients (13) .
In light of these data, investigations of glucose and glucose-precursor kinetics were performed in patients with chronic renal insufficiency. Turnover rates of alanine and glucose were determined in chronically azotemic patients and in normal control subjects with simultaneous primed injection-continuous infusions of [U-14C]alanine and [2-3H ] Hglucose. Alanine-glucose, precursor-product interrelationships were assessed and compared in the two groups. The roles of accelerated glucose fluix, of increased gluconeogenesis from alanine, and of impaired glucose disposal in the abnormal carbohydrate metabolism of chronic renal failure are discussed.
NI ET HOD S 10 healthy adults (5 men and .5 women) and 13 nondialyzed patients with chronic renal f;ailure (11 men and 2 women) were studied after obtaining informed consent in writing. All control subjects were wvithin 10% of' their desirable body weight (Mletropolitan Life Inisurance Co. tables), and they ranged in age f'rom 22 to 36 In the azotemic subjects, mean blood urea nitrogen, creatinine, hematocrit, and albumini were 99.8±8.2 mg/100 ml, 10.7 +1.2 mg/100 ml, 27+1% and 3.5±0.2 g/100 ml, respectively. None of'the patients had the nephrotic syndrome (24 h protein excretion > 3.0 g) or peripheral edema at the time of the study. All patients were maintained on a 2-g sodium, 2-g potassium, 40-g high biologic value protein diet made isocaloric to include 300 g carbohydrate for at least 3 days bef'ore the study. The patients were all normokalemic and not acidotic at the time of the study. Medications included varying dosages of dihydrotachysterol, phosphate binders, and sodium citrate solution. Patients taking additional medications required f'or the management of' associated conditions were included in this study only if' these medications wvere known not to interfere with carbohydrate metabolism. Three patients were known to be diabetic bef'ore the onset of renal f:ailure; patient S. B. was taking insulin, patient S. P. was taking chlorpropamiiide. 'Medications were omiiitted the morning of' the study.
Previously described isotope dilution methodology was modified slightly for the present study (15 Increased Gltucose Production and Gluconeogenesis in Chronic Azotemia ,uCi/kg) was given, followed by a continuous infusion of both isotopes (0.15 ,uCi/kg per h). Venous blood samples were obtained without tourniquet occlusion at 30-min intervals for 5 h while the patient was at absolute bedrest. Alanine (16) and glucose (17) were determined in neutralized perchloric acid extracts of whole blood in triplicate by fluorometric enzymatic techniques. Nonglucose reducing substances, present in higher than normal concentrations in azotemic patients (18) , are not measured by this glucosespecific assay which relies upon hexokinase (E.C.2.7.1.1.) and glucose-6-phosphate dehydrogenase (E.C.1.1.1.49). For determination of their specific activities, alanine (5) and glucose (19) were removed from neutralized perchloric acid extracts of blood by ion exchange chromatography. Because of the redistribution of alanine between erythrocytes and plasma in anephric man (20) and to minimize blood loss from the azotemic patients during the study, previously described recovery techni(lues (15) with plasma were modified for whole blood analysis with small volume samples (5 ml). Glucose recovery was determined for each individual blood sample analyzed and was greater than 95% in all instances. Alanine recoveries ranged from 93 to 99%. The amount of tritiuim label from [2-3H] glucose appearing in the alanine pool was insignificant. Greater than 95% of '14C label in all blood samples was accounted for by 14C label recovered in the sum of glucose plus alanine. Turnover rates for both glucose and alanine were calculated for each patient from the plateaui portion of each appropriate specific activity curve. Point-to-point calculations of metabolite production and utilization by modifications of the equations of Steele and colleagues were also performed as described previously (15, 21) . However, becauise these data did not significantly extend the data derived from the turnover calculations, they have not been incluided. Calctulations of precursor-produtct interrelationships for alanine and gluicose were based upon minor modifications of the equations described by Kreisberg et al. (19) . These modifications correct for loss of 14C label appearing in glucose because of fumarase randomization and stubsequent decarboxylation by P-enolpyruvate carboxykinase of four-carbon intermediates in the pathway of gluconeogenesis (22, 23) . Serum insulin was measured by double antibody radioimmunoassay (24) .
Statistical evaluation of data was performed with Student's t test after ascertaining normal distribution (25) . Results are expressed as the mean+SEM as the index of dispersion. Computational assistance was provided by the CLINFO project.
RESULTS
After initiation of the simultaneous isotope infusions, constant specific activity in glucose and alanine was observed in each subject no later than 210 min. In most, constant specific activity was reached between 120 and 150 min. As shown in Figs. 1A and 2A, constant specific activity of the 14C label in the circulating alanine pool was attained after 180 min of infusion in control subjects and in azotemic patients. In comparison, constant specific activity of 3H label in circulating glucose was evident after 150 and 210 min in normal volunteers and in patients with chronic renal failuire, respectively (Figs. 1C, 2C ). The appearance of' 14C label in the circulating glucose pool from [U-14C]alanine was determined to provide an index of the rate of gluconeogenesis, at least from alanine. Constant specific activity of the 14C label in glucose was observed by at least 270 min in all control and azotemic subjects (Figs. iB, 2B ). As shown in Table II , mean fasting blood glucose levels of the nondiabetic patients with chronic renal insuf: ficiency were increased 24.3% (P = 0.005) as compared to control subjects, and fasting immunoreactive insulin levels were increased 130% (P = 0.046). None of the nondiabetic azotemic subjects had fasting hyperglycemia (glucose > 6.67 mM). Calculated glucose turnover in control subjects was found to average 664 ±33.5 gmol/min. Glucose turnover was increased 55% in both the nondiabetic azotemic patients (P < 0.001) and in the total group of azotemic patients studiecd (P = 0.003). These increments in the data obtained from the azotemic patients were also statistically significant when expressed either on a per unit weight or body surface basis. Glucose turnover did not correlate with fasting glucose levels or body surface area in either controls or nondiabetic azotemic subjects, nor did glucose turnover rates correlate with the age of the azotemic subjects studied. No differences were found in fasting blood alanine levels between the various groups studied (Table III) . In control subjects, alanine turnover averaged 163 + 19.4 ,mol/min. Rates of alanine turnover in the entire azotemic population and in the nondiabetic subpopulation were increased 191% (P = 0.007) and 234% (P = 0.008), respectively. No correlation could be found between age, weight, body surface area, or fasting alanine level and the rate of alanine turnover in either the azotemic or control group.
Glucose production from alanine was estimated by the rate of 14C label appearance in glucose from [U-14C]alanine. In control subjects, glucose produced from alanine was 21.7+2.24 ,umol/min, amounting to 3.21+0.42% of total glucose production (Table IV) . In the nondiabetic azotemic subjects, glucose production from alanine was increased 221% (P = 0.003), whereas in the entire azotemic population the rate of gluconeogenesis was increased 192% (P = 0.02). The relative contribution of gluconeogenesis from alanine to total glucose production was also increased to 9.74 +3.00% (P = 0.059) in the nondiabetic subjects with chronic renal failure and to 8.64+2.38% (P < 0.05) in the entire group of azotemic patients. The rate of glucose production from alanine correlated well with the rate of alanine tuirnover in both control subjects (r = 0.729, P = 0.017), and the entire azotemic population (r = 0.626, P = 0.022) as shown in Figs. 3 and 4 , respectively. However, a lesser degree of correlation between rates of gluconieogenesis from alanine and alaniine turnover wvas found in the nonidiabetic patients with renal failure (r = 0.597, P = 0.069).
In control subjects, 40.2+3.86 ,mol/min of alanine were uitilized for glticoneogenesis, accounting for 25.4 Values shown are the means ±SEM for each determination. P represents the probability of rejection of the null hypothesis of equality between the footnoted population mean and the appropriate control mean. *P > 0.1.
* P < 0.01. § P < 0.05. + 1.52% of total alanine utilization (Table V ). In the nondiabetic azotemic patients, alanine utilization for gluconeogenesis was increased 305% (P = 0.034). However, the fraction of total alanine utilization accounted for by gluconeogenesis was unchanged in azotemic subjects as compared to control subjects.
DISCUSSION
Isotope dilution techniques have been widely used for the in vivo study of intermediary metabolism, particularly of glucose and glucose precursors (26) . Simultaneous infusions of labeled glucose and gluconeogenic precursors have been employed previously to obtain accurate data concerning gluconeogenesis in vivo (27) . The use of [2-3H]glucose provides a relatively good estimation of total glucose production because detritiation occurs by the action of phosphohexoseisomerase (28 Although observations concerning glucose and glucose-precursor kinetics in chronic renal failure are previously unreported (1, 36) , WZestervelt observed that insulin-stimulated rates of glucose uptake in forearm studies from azotemic patients were decreased 75% compared to rates observed with control subjects (37) . Decrements in blood gltucose concentration after intravenous insulin injection (2, 4, 38) or tolbtutamide injection (18, 38) were diminished and slower in development in azotemic as compared to control subjects. In this study, as in other studies, increased fasting immunoreactive instulin levels and normal fasting glucose levels were found in chronic azotemia (2, 3, 18, 38, 39) . However, the extent to which these increased immunoreactive insulin levels may reflect the accumulation of proinsulin was not ascertained. The results of previouis stuidies have been interpreted to suggest the presence of insulin resistance in chronic renal failure. The results of this study demonstrate increased basal glucose flux in chronic renal insufficiency. This increased glucose prodtuction observed in the postabsorptive state may result in part from an increased rate of gluconeogenesis from alanine because the latter was inereased 192% in the azotemic subjects as compared to conitrol subjects. The increased gluconeogenesis in turn appears to depend in part upon an increased rate of alanine productioni, without which gluconeogenesis could not be sustained for any significant period. In addition, an independent activation of hepatic alanine metabolism towards gluconeogene- Values shown are the means±SENM for each determination. P represents the probability of rejection of the null hypothesis of equality between the footnoted population mean and the appropriate control mean. total glucose prodtictioni conitrib)uted l)y gliuconeogeniesis w-as inicreased 169% ini azotemiic subljects, and I)ecause alaninie lev-els were unchaiiged desp)ite a thre-efolId inicrease in atlaninie delivery. In niormials, increased alaniniie delivery as providled by ani alaniniie inifutsion resuilts ini incereased alaninie levels (40) . These finidings of' increased glutconeogeniesis lin atzoteinici miani correlate wvell with finin(iigs of increased in vitro hepatic gluiconeogeniesis in the urem-ic rat (12, 13 (46) and( hepattic gluiconieogeniesis f'romi thiree carbon prectirsors (47) . Whereas the eff'ect of' parathyroid hiormionc o)n adlenylate cyclase activity is less thian-the stiimutlation produtced by epiniephri ne o)r glutcagoni, parathyroid h-ormionie levels are suibstanltially elevated in chironiic renial f'ailuire (:36) andi( may' contributetc to the inicreased1 hiepatic gluiconieogemmesis. Ihoweve-r, a single study hias suiggestedI that parathyroi dectomy h-as nio ef'fect tipon thie abnormal gluicose mectabolism of' chiron-ic-renial fhailutre (48) .
In sumnmarv, the finidinigs of the p)rcsent studyt demin)mlstrate incrcasedl gluicose production, uitilizationi, and gluconeogenesis in patienits with chlronici renial t'aluire. InicreasedI glucose produiction f'romi alaniIiie appears to derive f'romi a primary abnormality of'hepatic gILucose mietabolismi. Rates of' alaniniie produtction atlso wvere substantially incereatsed su ggestliug ani indltepenidenit abniormiality )1' alanine metabolism in L)eripberal tissuies sutch as skeletal inniscle. Relative elevationis of' f'astiing gluicose and ilInMuLnoreactive inisulini levels were ol)served in azotemi-ic pattienits. Taken as at whole, the finin(iigs ofI' incereasedi alaninie producttioni, inicreatsedi glucose production, incereatse(l gluconeo)genesi s, and imipaired gluicose dlisposal, all o)f which are processes reguilatedi by insuinii, suiggest ani undierlyinig loepattic as well as peripheral iinsensitivitv to insutlini actioni in chironici renial insufficiencx'.
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